An SLGT-2 inhibitor is soon expected to be available for use in chronic kidney disease (CKD) patients in Korea.

According to industry sources, the indication of AstraZeneca’s diabetes treatment ‘Forxiga(dapagliflozin)’ will be expanded to ‘the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes' within a few days.

After receiving approval from the US FDA in April, the company had immediately begun the approval process in other major countries including Korea. In September, the company received EMA approval for the additional indication in September.

With the indication, Forxiga can be used to reduce the risk of sustai